Compare LQDA & ATMU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | ATMU |
|---|---|---|
| Founded | 2004 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.4B |
| IPO Year | 2020 | 2023 |
| Metric | LQDA | ATMU |
|---|---|---|
| Price | $34.32 | $44.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $54.38 | ★ $62.60 |
| AVG Volume (30 Days) | ★ 4.6M | 591.9K |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | N/A | ★ 0.54% |
| EPS Growth | ★ 51.81 | 12.61 |
| EPS | 1.26 | ★ 1.37 |
| Revenue | $158,320,000.00 | ★ $1,764,300,000.00 |
| Revenue This Year | $357.27 | $14.05 |
| Revenue Next Year | $1.34 | $5.07 |
| P/E Ratio | ★ $27.38 | $32.34 |
| Revenue Growth | ★ 1031.18 | 5.67 |
| 52 Week Low | $21.97 | $40.75 |
| 52 Week High | $93.61 | $66.50 |
| Indicator | LQDA | ATMU |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 46.23 |
| Support Level | $32.63 | $43.76 |
| Resistance Level | $42.62 | $45.68 |
| Average True Range (ATR) | 2.90 | 1.33 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 23.72 | 53.50 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.